The Dudley Group
NHS Foundation Trust

Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-052026-0002430

Date: 12.06.2026

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000, please see response below.

Q1. How many new patients were treated for any condition by the Trust's Dermatology Department in the latest 3-month period of January, February and March 2026 (or the latest 3 months available) with the treatments I have provided below?
If you are able to, could you please provide the split of new patients who received their treatment for Psoriasis.
Please can you define a "new patient" as a patient who is receiving any of the treatments listed below for the first time. If a patient received any of the below treatments in 2024 or previous years, they can be classed as a new patient for this period.

Patient counts for specific indications are taken from Bluteq figures.

Q1: In the 3-months, Jan-Mar 26, the following number of patients were newly issued* the listed treatments (by the Dermatology Department) for, i) any condition and ii) Psoriasis:**
***Newly issued refers to a patient that has been issued the named treatment during the time period in question but has NOT been issued ANY of the named treatments in the 9 months prior to that (Apr25-Dec25)**

****Patients who have been newly issued the treatment AND have a Bluteq for the named treatment and Indication**
☐

	PT Count	
Treatment	**i) any condition**	**ii) **Psoriasis**
Adalimumab [Humira]	0	0
Adalimumab [All Biosimilars]	10	8
Apremilast [Otezla]	0	0
Apremilast [Generic]	0	0
Etanercept [Enbrel]	0	0
Etanercept [All Biosimilars]	0	0
Infliximab [Remicade]	0	0
Infliximab [All Biosimilars]	1	0
Ustekinumab [Stelara]	0	0
Ustekinumab [All Biosimilars]	2	2
Bimekizumab [Bimzelx]	0	0

Brodalumab [Kyntheum]	0	0
Certolizumab [Cimzia]	0	0
Deucravacitinib [Sotyktu]	0	0
Dimethyl Fumarate [Skilarence]	0	0
Guselkumab [Tremfya]	0	0
Ixekizumab [Taltz]	0	0
Risankizumab [Skyrizi]	0	0
Secukinumab [Cosentyx]	0	0
Spesolimab [Spevigo]	0	0
Tildrakizumab [Illumetri]	0	0

Q2. How many new patients were treated for any condition by the Trust's Rheumatology Department in the latest 3-month period of January, February and March 2026 (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Axial Spondyloarthritis (axSpA), Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA).

- In the 3-months, Jan-Mar 26, the following number of patients were newly issued* the listed treatments (by the Rheumatology Department) for, i) any condition, ii) Axial Spondyloarthritis (axSpA), iii) Rheumatoid Arthritis (RA), and iv) Psoriatic Arthritis (PsA):**
***Newly issued refers to a patient that has been issued the named treatment during the time period in question but has NOT been issued ANY of the named treatments in the 9 months prior to that (Apr25-Dec25)**
****Patients who have been newly issued the treatment AND have a Bluteq for the named treatment and Indication**
☐

	PT Count			
Treatment	**i) any condition**	**ii) Axial Spondyloarthritis (axSpA)****	**iii) Rheumatoid Arthritis (RA)**	**iv) Psoriatic Arthritis (PsA)**
Abatacept [Orencia]	0		0	0
Adalimumab [Humira]	0	0	0	0
Adalimumab [All Biosimilars]	30	5	16	7
Apremilast [Otezla]	0			0
Apremilast [Generic]	0			0
Baricitinib [Olumiant]	0		0	
Bimekizumab [Bimzelx]	1	0		1
Certolizumab [Cimzia]	1	0	0	1
Etanercept [Enbrel]	0	0	0	0
Etanercept [All Biosimilars]	2	0	1	0
Filgotinib [Jyseleca]	0		0	
Golimumab [Simponi]	0	0	0	0
Golimumab [All Biosimilars]	0	0	0	0
Guselkumab [Tremfya]	0		0	0
Infliximab [Remicade]	0	0	0	0
Infliximab [All Biosimilars]	1	0	0	0
Ixekizumab [Taltz]	0	0		0

Risankizumab [Skyrizi]	0			0
Rituximab [MabThera]	0		0	
Rituximab [Biosimilars]	21		19	
Sarilumab [Kevzara]	0		0	
Secukinumab [Cosentyx]	2	0		2
Tocilizumab [RoActemra]	0		0	
Tocilizumab [Biosimilars]	5		2	
Tofacitinib [Xeljanz]	0	0	0	0
Upadacitinib [Rinvoq]	1	0	0	0
Ustekinumab [Stelara]	0			0
Ustekinumab Biosimilar	0			0

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust